Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
PURPOSE: This phase I/II trial is studying the side effects of imatinib mesylate and to see
how well it works in treating patients with recurrent or refractory aggressive fibromatosis.